ENGLEWOOD, Colo., July 20 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today announced the publication “Insights into pediatric multi-system inflammatory syndrome and COVID-19.”
“This newly described syndrome in children”, explained Ampio founder and principle author, Dr. David Bar-Or, MD, “resembles Kawasaki Disease and exhibits many signs, symptoms and pathology that could be treated by intravenous AmpionTM either alone or in combination with intravenous immunoglobulins (“IVIG”)”. A commentary describing the involvement of prostaglandins and cytokines in this syndrome and the Ampion in-vitro experiments demonstrating beneficial effects for the same, just published in Clinica Chimica Acta: 510 (2020) 121-122, can be accessed at: https://authors.elsevier.com/c/1bPpm2G2LyTE3. Ampio continues to evaluate the potential use of Ampion in this condition as a safe, effective and alternative/addition to existing therapies.
About Ampio Pharmaceutical
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. Ampio’s lead drug, Ampion, is backed by an extensive patent portfolio with intellectual property protection extending through 2032, and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (“BPCIA”).
Forward Looking Statements
Ampio’s statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “believe,” “expect,” “plan,” “anticipate,” and similar expressions. These forward-looking statements include statements regarding Ampio’s expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (“BLA”), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat acute respiratory distress syndrome (“ARDS”) induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio’s filings with the Securities and Exchange Commission, including without limitation, under Ampio’s Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Dan Stokely, CFO
Phone: (720) 437-6500
Ampio Pharmaceuticals, Inc.